** Shares of Australia's Clarity Pharmaceuticals CU6.AX rise as much as 11.4% to A$3.72, their highest since November 25

** Clinical stage radiopharma firm says it will commence a phase III trial of Cu-64 Sartate in patients with neuroendocrine tumours

** Co says to commence trial after a successful end of phase meeting with U.S. FDA in which all key components of proposed trial design were agreed upon with the agency

** CU6 down 14.4% YTD

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))